EUVIMEDEUVIMED entdecken
Crossref

STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma

Matthew T Ye iD, Zhuang Zuo, Steliana Calin, Yaling Yang, M James You

European Journal of Haematology · 2026-07 · 117 (1) · 258-266

DOI: 10.1111/ejh.70174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 08.04.2026. Verfasst von Matthew T Ye und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, STAT3 Transcription Factor, Mutation, STAT5 Transcription Factor. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Plasma cell myeloma is a heterogeneous hematologic malignancy characterized by clonal expansion of plasma cells. While RAS‐MAPK pathway mutations are known high‐risk features, the clinical relevance of STAT3 / STAT5 mutations remains unclear.

Method

We analyzed 16 myeloma patients with STAT3 / STAT5 mutations identified by next‐generation sequencing (9 STAT3 , 5 STAT5A , 2 STAT5B ) and compared them with 32 mutation‐negative controls.

Results

STAT3 / STAT5 mutations were present at initial diagnosis in all eight patients with available initial sequencing data, suggesting these are early events in pathogenesis. STAT3 / STAT5 mutations were the sole mutations in five patients, while 10 had co‐mutations, most frequently in KRAS / NRAS ( n = 5) and TP53 ( n = 3). In co‐mutated cases, STAT3 / STAT5 represented the dominant clone in 4 and co‐dominant in 6. All mutations were missense, with 63% involving the SH2 domain. Compared with controls, STAT3 / STAT5 ‐mutated patients had higher serum lactate dehydrogenase levels, higher incidence of IgA paraprotein, higher R‐ISS stage, more complex karyotype, and frequent CKS1B gain/amplification. Overall survival was significantly shorter in patients with STAT3 / STAT5 mutations (median 42 vs. 72 months, p < 0.0001).

Conclusion

STAT3 / STAT5 mutations are early, dominant, and potentially pathogenic events in plasma cell myeloma. Their association with adverse clinical features and inferior survival supports their routine assessment and potential therapeutic targeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaSTAT3 Transcription FactorMutationSTAT5 Transcription FactorHumansAgedPrognosisMaleMiddle AgedFemaleAdultAged, 80 and overDNA Mutational AnalysisHigh-Throughput Nucleotide SequencingNeoplasm StagingBiomarkers, Tumor

Stichwörter der Autor:innen

STAT3STAT5ASTAT5Bplasma cell myelomapoor prognosis

Substanzen

STAT3 Transcription FactorSTAT5 Transcription FactorSTAT3 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.

ORCID-Profile: Matthew T Ye

Zitieren

APA

Ye, M. T., Zuo, Z., Calin, S., Yang, Y., & You, M. J. (2026). STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma. European Journal of Haematology, 117(1), 258-266. https://doi.org/10.1111/ejh.70174

Vancouver

Ye MT, Zuo Z, Calin S, Yang Y, You MJ. STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma. European Journal of Haematology. 2026;117(1):258-266. doi:10.1111/ejh.70174

BibTeX
@article{Ye2026,
  author = {Ye, Matthew T and Zuo, Zhuang and Calin, Steliana and Yang, Yaling and You, M James},
  title = {STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {1},
  pages = {258--266},
  doi = {10.1111/ejh.70174}
}
Kostenlos starten →